CXCR4 and neoplasm: Recent reports suggest that sorafenib treatment can elicit hypoxic to activate HIF-1α in tumor cells and stromal cells in tumor microenvironment, leading to increases in expressions of CXCR4 and its ligand SDF-1α in HCC [21, 22].